Risk/Benefit Conclusions
Current practices and standards of care support CIU as OTC indication
- Multiple refills
- OTC medications
- Limited physician oversight
Consumers currently self-treat with sedating OTC antihistamines for all forms of urticaria without labeling for this indication
CIU patients would benefit from OTC access to first-line, non-sedating therapy for recurrent episodes
Proper OTC labeling and patient education will aid consumers in better treatment of CIU